HomeCompareBMY vs CME

BMY vs CME: Dividend Comparison 2026

BMY yields 4.17% · CME yields 1.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CME wins by $3.93M in total portfolio value· pulled ahead in Year 4
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
CME
CME
● Live price
1.75%
Share price
$297.58
Annual div
$5.20
5Y div CAGR
85.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.05M
Annual income
$3,278,693.93
Full CME calculator →

Portfolio growth — BMY vs CME

📍 CME pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYCME
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + CME cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
CME pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
CME
Annual income on $10K today (after 15% tax)
$148.53/yr
After 10yr DRIP, annual income (after tax)
$2,786,889.84/yr
At 15% tax rate, CME beats the other by $2,753,039.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + CME for your $10,000?

BMY: 50%CME: 50%
100% CME50/50100% BMY
Portfolio after 10yr
$2.08M
Annual income
$1,659,258.80/yr
Blended yield
79.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
CME
Analyst Ratings
13
Buy
17
Hold
5
Sell
Consensus: Hold
Price Target
$311.83
+4.8% upside vs current
Range: $300.00 — $340.00
Altman Z
0.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
CME buys
0
No recent congressional trades found for BMY or CME in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYCME
Forward yield4.17%1.75%
Annual dividend / share$2.49$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%85.4%
Portfolio after 10y$120.5K$4.05M
Annual income after 10y$39,823.66$3,278,693.93
Total dividends collected$91.0K$3.96M
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldHold
Analyst price target$62.73$311.83

Year-by-year: BMY vs CME ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrCME PortfolioCME Income/yrGap
1$11,271$571.12$11,024$323.97+$247.00BMY
2$12,884$824.20$12,414$618.83+$470.00BMY
3$14,993$1,206.32$14,491$1,207.51+$502.00BMY
4← crossover$17,839$1,797.27$17,948$2,442.23$109.00CME
5$21,826$2,738.11$24,445$5,241.07$2.6KCME
6$27,643$4,289.31$38,525$12,368.84$10.9KCME
7$36,534$6,955.64$74,998$33,775.95$38.5KCME
8$50,861$11,770.13$194,178$113,930.22$143.3KCME
9$75,402$20,980.23$718,883$511,112.41$643.5KCME
10$120,504$39,823.66$4,047,898$3,278,693.93$3.93MCME

BMY vs CME: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

CMEFinancials

CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income products. The company also provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois.

Full CME Calculator →
📬

Get this BMY vs CME comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.